Despite innovation to date in gene therapy, safety concerns with adeno-associated virus (AAV) vectors and uneasiness around cost and affordability has brought into focus the need for even more advancement in the field. In this Pharma Live article, Precision’s Phil Cyr discusses some of the innovations that are occurring to address these issues.
CLICK HERE to read the full article